Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease

@inproceedings{Sumner2018AntibodyEF,
  title={Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease},
  author={Isabelle L. Sumner and R. A. Edwards and Ayodeji A. Asuni and Jessica L Teeling},
  booktitle={Front. Neurosci.},
  year={2018}
}
There are nearly 50 million people with Alzheimer's disease (AD) worldwide and currently no disease modifying treatment is available. AD is characterized by deposits of Amyloid-β (Aβ), neurofibrillary tangles, and neuroinflammation, and several drug discovery programmes studies have focussed on Aβ as therapeutic target. Active immunization and passive immunization against Aβ leads to the clearance of deposits in humans and transgenic mice expressing human Aβ but have failed to improve memory… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 110 REFERENCES

Truncated and modified amyloid-beta species

  • Alzheimer's Research & Therapy
  • 2014
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.

  • The New England journal of medicine
  • 2014
VIEW 1 EXCERPT
HIGHLY INFLUENTIAL